Skip to main content
SpringerLink
Log in

Bevacizumab in First-Line Treatment of Metastatic Breast Cancer

A Viewpoint by David Miles

  • Adis Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Sem Oncol 2003; 30 (5 Suppl. 16): 117–24

    Article  CAS  Google Scholar 

  2. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23(4): 792–9

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mount Vernon Cancer Centre, Northwood, Middlesex, England

    David Miles

Authors
  1. David Miles
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miles, D. Bevacizumab in First-Line Treatment of Metastatic Breast Cancer. Drugs 67, 1800 (2007). https://doi.org/10.2165/00003495-200767120-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767120-00010

Keywords

Search

Navigation